Advanced search
Publication Cover
Open Access Journal of Urology Volume 3, 2011 - Issue
Journal homepage
33
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies

Marc C Gittelman1 South Florida Medical Research, Aventura, Florida, USACorrespondence[email protected]
,
Leonard S Marks2 University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California, USA
,
Lawrence A Hill3 Watson Laboratories, Salt Lake City, Utah, USA
,
Weining Volinn3 Watson Laboratories, Salt Lake City, Utah, USA
&
Gary Hoel3 Watson Laboratories, Salt Lake City, Utah, USA
Pages 1-5 | Published online: 22 Dec 2010

References

  • Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by α1A-(α1C-) adrenoceptor subtype. Br J Pharmacol. 1995;115:781–786.
  • Schwinn DA, Roehrborn CG. α1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193–199.
  • Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9:181–190.
  • Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723–728.
  • Rudner XL, Berkowitz DE, Booth JV et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999;100:2336–2343.
  • Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, α1A-adrenoceptor-selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48:250–2158.
  • Yamada S, Okura T, Kimura R. In vivo demonstration of α1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther. 2001;296:160–167.
  • Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I. Tissue selectivity of KMD-3213, an α1-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000;164:578–583.
  • Yamagishi R, Akiyama K, Nakamura S, et al. Effect of KMD-3213, an α1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol. 1996;315:73–79.
  • Akiyama K, Hora M, Tatemichi S, et al. KMD-3213, a uroselective and long-acting α1A-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther. 1999;291:81–91.
  • Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–2640.
  • Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009;74:1318–1322.
  • Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–1557. Discussion 1564.
  • Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol. 2007;51:1522–1533.
  • American Urological Association. Clinical Guidelines: Management of BPH (2003/Updated 2006). Chapter 1: AUA Guidelines on the Management of Benign Prostatic Hyperplasia: Diagnosis and Treatment Recommendations. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph. Accessed 2009 May 14.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.